Tomas Neilan, MD, MPH
Tomas Neilan, MD, MPH
Director, Cardio-Oncology Program
Co-Director, Cardiac MR PET CT Program
About Tomas Neilan, MD, MPH
Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program.
Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.
Departments, Centers, & Programs:
Clinical Interests:
- Cardio-oncology
- Cardiac imaging
- Heart failure
- Echocardiography
- Cardiac magnetic resonance imaging (Cardiac MRI)
Treats:
- Adult
Languages:
- Irish
Locations
Cardiac Unit Associates
55 Fruit Street
Boston, MA 02114-2696
Phone: 617-643-9789
Fax: 617-724-6767
Medical Education
- MD, University College Dublin
- MBBCh, BAO, University College Dublin School of Medicine
- Residency, Massachusetts General Hospital
- Residency, Mater Misericordiae University Hospital
- Fellowship, Brigham and Women's Hospital
- Fellowship, Massachusetts General Hospital
- Fellowship, Mater Misericordiae University Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Cardiovascular Disease, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - New York
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Neilan's primary research focus is on how we can improve on both the detection and treatment of the potential cardiovascular complications after chemotherapy and radiotherapy. Dr. Neilan is also interested in the thoughtful use of advanced imaging techniques to improve our understanding and treatment of all patients with cardiovascular disease especially those who are at risk of heart failure.
Publications
-
View my most recent publications at PubMed
Select Publications:
- Neilan et al. Iloprost attenuates doxorubicin-induced cardiac injury without compromising tumor suppression. European Heart Journal, 2006
- Neilan et al. Tissue Doppler Imaging Predicts Left Ventricular Dysfunction in a Murine Model of Anthracycline Induce Cardiac Injury. European Heart Journal, 2006
- Neilan at al. Disruption of COX-2 Modulates Gene Expression and the Cardiac Injury Response to Doxorubicin. American Journal of Physiology-Heart and Circulatory Physiology, 2006
- Neilan et al. Disruption of Nitric Oxide Synthase-3 Protects against the Cardiac Injury, Dysfunction, and Mortality induced by Doxorubicin. Circulation, 2007
- Neilan et al. Left Ventricular Mass by Cardiac Magnetic Resonance Imaging and Adverse Cardiovascular Outcomes in Patients treated with Anthracycline-based Chemotherapy. Am J Cardiol. 2012
- Neilan et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013
- Neilan et al. Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction. Expert Rev Cardiovasc Ther. 2014
- Neilan et al. Detection of Cardiac Toxicity Due to Cancer Treatment: Role of Cardiac MRI. Curr Treat Options Cardiovasc Med. 2015